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Lysophosphatidic acid (LPA) initiates demyelination following peripheral nerve injury, which causes
neuropathic pain. Our previous in vivo and ex vivo studies using mice have demonstrated that LPA-
induced demyelination of spinal dorsal roots is attributed by the LPA1-type receptor-mediated down-
regulation of myelin-related molecules, such as MBP and MPZ. In this study using S16 mature-type
Schwann cells, we found that LPA-induced down-regulation of myelin-related genes is attributed by
the activation of LPA1 receptor, Rho kinase, and p300, leading to an acetylation of NFkB, which down-
regulates the transcription of Sox10, MBP and MPZ genes.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Acute pain such as nociceptive and inﬂammatory pain plays
important roles as an alarm, and this type of pain is sensitive to
nonsteroidal anti-inﬂammatory drugs and opioids. Chronic pain
including neuropathic pain, on the other hand, is refractory to these
medical treatments. Neuropathic pain is often characterized by
abnormally hyper-responsive sensory perception, called hyper-
algesia or allodynia, in which innocuous (tactile) stimuli cause
intense pain. In a series of our studies, we have proposed that
lysophosphatidic acid (LPA)-mediated demyelination of sensory
neurons is one of neurobiological mechanisms underlying neuro-
pathic allodynia (1). As the cluster of biochemical events involved
in demyelination are being reconstructed, the unique role of LPA in
initiation of neuropathic pain through demyelination is becoming
clearer (1e3). We have revealed that LPA functions as an initiator of
neuropathic pain, and moreover, LPA itself ampliﬁes LPA biosyn-
thesis through an activation of LPA3 receptor and microglia (4,5).
This ampliﬁed LPA acts on dorsal root as a retrograde signal, which
in turn results in demyelination through LPA1 receptor. We found
that LPA-mediated demyelination occurs in in vivo and ex vivo
systems and this signaling is mediated by Rho/Rho kinase (ROCK)
pathway (1,2), while detailed cell-based mechanisms remain
elusive. In this study, we report that LPA initiates down-regulationrmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).of myelin-related gene expression via LPA1 in S16 cells, a mature-
type of Schwann cell line, and this signaling is associated with
Rho/ROCK pathway and unique acetylation of NFkB.
S16 cell line was purchased from ATCC (Manassas, VA) and
maintained with Dulbecco's modiﬁed Eagle's medium (DMEM)
containing 10% FBS (Gibco, Grand Island, NY) supplemented with
100 IU/ml penicillin G and 100 mg/ml streptomycin at 37 C in a
humidiﬁed 5% CO2 atmosphere.
For quantitative PCR, S16 cells were plated onto 6-well plates at
4.0 104 cells per well in DMEM containing 10% FBS. After 48 h, the
cells were serum-starved in DMEM containing 0.1% BSA for 3 h, and
then pre-treated with 1 mM of the following compounds: Ki16425
(a general gift from KIRIN Brewery Co., Ltd, Gunma, Japan), Y27632
(SigmaeAldrich, St Louis, MO), or C646 (SigmaeAldrich) for 30min.
The cells were then treated with vehicle or LPA (1-oleoyl-2-
hydroxy-sn-3-glycerol-3-phosphate, Cayman Chemical, Ann Ar-
bor, MI) for 3 h. Total RNA was isolated using TRIzol (Life technol-
ogies, Gaithersburg, MD) according to the manufacturer's
instructions. cDNAwas synthesized with PrimeScript RT reagent kit
(Takara Bio, Inc., Japan). Quantitative PCR analysis was performed
using GeneAce SYBE qPCRMix (Nippon Gene, Japan) on LightCycler
480II Real-Time PCR system (Roche, Indianapolis, IN). The PCR
conditions were as follows: 95 C for 30 s and 60 C for 60 s with
initial activation of enzyme at 95 C for 10 min for a total of 40
cycles. The following primer sets were used: Mbp forward: 50-
CTCCCAAGGCACAGAGACA-30 and reverse: 50-AGGGAGCCG-
TAGTGGGTAGT-30; Mpz forward: 50-GGTGGTGCTGTTGCTGCTG-30nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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GCTATCCAGGCTCACTACAAGAGT-30 and reverse: 50-
CTCTGTCTTTGGGGTGGTTG-30; GAPDH forward: 50-CCACGG-
CAAGTTCAACGGCACAGT-30 and reverse 50-CAGCGGAAGGGGCG-
GAGATGAT-30. The data were analyzed using the delta cycle
threshold method and the expression level of each gene was
normalized to GAPDH.
For phalloidin staining, cells were seeded onto a lab-Tek-8-
chamber slide (NUNC, Rochester, NY) at 2.0  104 cells per well.
The next day, after the serum-deprivation culture for 3 h, the cells
were pre-treated with Ki16425, Y27632, or C646, followed by
stimulated with vehicle or LPA as mentioned above. The cells were
washed with PBS and ﬁxed with 4% PFA for 1 h at room temper-
ature. After ﬁxing, rhodamine-phalloidin (0.05 U/mL, Invitrogen,
Carlsbad, CA) was applied and incubated for 1 h. After PBS wash,
the slides were mounted with Vectashield containing DAPI (Vec-
tor Laboratories, Burlingame, CA). The stained cells were placed
on a Zeiss LSM 710 inverted laser scan confocal to capture the
images. We used a 20 EC Plan-Neoﬂuar lens (Zeiss) for all
experiments.
As for western blotting, S16 cells were plated onto 6-well plates
at 4.0  104 cells per well. After 48 h, the cells were serum-starved
and pre-treated with Ki16425, Y27632, or C646 followed by treated
with LPA as described above. The cells were collected and subjected
to western blot analysis to detect NFkB and acetylated NFkB (ac-
NFkB). Proteins were separated by SDS-PAGE and transferred to a
Trans-Blot Turbo Mini PVDF membrane (Bio-Rad, Hercules, CA)
using a Trans-Blot Turbo transfer system. The membranes were
blocked with Block Ace (Dainihon Pharmaceutical, Japan) and
probed with anti-NFkB, anti-ac-NFkB (#3034 and #3045, respec-
tively from Cell Signaling Technology; 1:1000 dilution), or anti-b-
actin (sc-47778, Santa Cruz Biotech; 1:1000 dilution) at 4 C over-
night. After washing, the membranes were reacted with horse-
radish peroxidase-conjugated secondary antibody (Promega;Mouse DR
Mbp M
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Fig. 1. Expression of LPA receptors in mouse dorsal root and S16 cells, and LPA-mediated
LPA receptor in mouse dorsal root (A) and S16 cells (B) was determined by quantitative real
expression level of Mbp (C), Mpz (D), and Sox10 (E). The mRNA levels were normalized using
one-way ANOVA).1:10,000 dilution) and developed using the SuperSignal chem-
iluminescence reagent (Thermo Scientiﬁc, Rockford, IL).
For statistical analysis, one-way ANOVAwas applied followed by
Dunnett's test formultiple comparisons (GraphPad Prism6). Results
were shown as means ± SEM.
We ﬁrst determined the expression level of LPA receptors in
mouse dorsal root (DR) andmatured Schwann cell line, S16 cells. As
shown in Fig. 1A and B, quantitative PCR analysis revealed that LPA1
receptor was dominantly expressed in both preparations. Mouse
DR ﬁbers most abundantly express LPA1, however, the expression of
LPA4e6 was very low, while LPA2 and LPA3 expression was negli-
gible. In S16 cells, LPA1 is also the most abundant, followed by LPA4,
while other subtypes were negligible. The addition of LPA at
0.3e3 mM to S16 cells caused signiﬁcant decreases in gene ex-
pressions of myelin basic protein (MBP) and myelin protein zero
(MPZ), and their upstream transacting factor, Sox10 by 20e30% of
control (Fig. 1CeE). The degree of decrease is equivalent to those
found in nerve injury- or LPA-induced in vivomodels (1), or ex vivo
model using dorsal root ﬁbers (2). It should be noted that LPA1 gene
expression did not change after LPA induction in S16 cells (data not
shown).
For the purpose of pharmacological characterization of Ki16425,
a selective inhibitor of LPA1 and LPA3 without afﬁnity to LPA4e6 (6),
and Y27632, a speciﬁc ROCK inhibitor, the effects of these inhibitors
on LPA-induced stress-ﬁber formation were evaluated by use of
phalloidin-staining in S16 cells. As shown in Fig. 2A and B, the
addition of LPA caused an intense stress-ﬁber formation. The co-
treatment with Ki16425 or Y27632 completely abolished the LPA-
induced stress ﬁber formation, while these inhibitors alone had
no signiﬁcant changes (Fig. 2CeF). As shown in Fig. 2G, the LPA-
induced down-regulation of Mbp, Mpz, and Sox10 gene expres-
sion was completely inhibited by Ki16425, suggesting that LPA1
receptor is responsible for these mechanisms, since LPA3 receptor is
not expressed in S16 cells. In addition, Ki16425-treatment did notS16 cells
pz Sox10
E
myelin-related gene regulation. Total RNAwas extracted and expression level of each
-time PCR. S16 cells were treated with 0.3, 1.0, or 3.0 mM LPA for 3 h and examined the
GAPDH (mean ± SEM, n ¼ 3, *p < 0.05 and **p < 0.01 (versus vehicle control) based on
Fig. 2. LPA1-mediated stress-ﬁber formation in S16 cells, and involvement of LPA1, Rho/ROCK, and p300 signaling in myelin-rerated gene expression. S16 cells were
stimulated with vehicle (A), or 10 mM LPA (B) for 1 h after 3 h serum-starvation. The cells were pretreated with Ki16425 (1 mM) or Y27632 (1 mM) for 30 min (C and E) followed by
the stimulation of LPA (10 mM) for 1 h (D and F). After treatment with LPA, the cells were ﬁxed and stained with rhodamine-phalloidin to detect actin stress ﬁbers. The images were
captured with a confocal ﬂuorescence microscope. Scale bar: 50 mm. The cells were pretreated with 0.1% BSA (vehicle), Ki16425 (1 mM) (G), Y27632 (1 mM) (H) or C646 (1 mM) (I) for
30 min, then treated with 1 mM LPA for 3 h. Total RNA was isolated and quantitative real-time PCR was performed to determine the expression of Mbp, Mpz, and Sox10. The mRNA
levels were normalized using GAPDH (mean ± SEM, n ¼ 6, **p < 0.01 (versus vehicle control) based on one-way ANOVA. N.S. represents no signiﬁcant).
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blockade of down-regulation was also observed by the treatment
with Y27632 (Fig. 2H), though either inhibitor alone had no sig-
niﬁcant effects on the expression of myelin-related genes. These
ﬁndings conﬁrmed our previous in vivo studies that the LPA1-re-
ceptor-mediated demyelination is mediated by its downstream
Rho/ROCK signaling (1).
Chen and others reported that deacetylation of NFkB by HDAC1/
2 are critical for myelination in Schwann cells (7,8). On the other
hand, p300 and ac-NF-kB complex induces chromatin modiﬁca-
tions, such as recruitment of histone H3K4 or K9 methyl-
transferases. Moreover, the ac-NF-kB/p300 complex represses
expression of Sox10, a transcriptional factor and regulates the
myelin-related genes (7). In addition, there are some reports that
ROCK phosphorylates p300 and activates its acetyltransferase ac-
tivity (9). However, the link between the extracellular signal and
the subsequent intracellular signaling upstream of NFkB-acetyla-
tion remains unclear. Here we examined the effects of C646, an
inhibitor of p300 (10), which is one of downstream factors of ROCK
and a transcriptional co-activator with acetyltransferase activity
(11). As shown in Fig. 2I, C646 signiﬁcantly attenuated the down-
regulation of gene expression of Mbp and Mpz as well as Sox10.
In the western blot analysis, on the other hand, LPA at 1 and
10 mM increased the levels of ac-NF-kB in S16 cells, while nochange was observed in the levels of non-ac-NF-kB (Fig. 3A). The
pretreatment with 1 mM Ki16425 inhibited the acetylation of
NFkB by LPA, while Ki16425 alone showed no effect. Quantitative
analysis demonstrated that LPA-induced increase in the ratio of
ac-NF-kB to non-ac-NF-kB and its blockade by Ki14625 were
signiﬁcant (Fig. 3B). Quite similar ﬁndings were observed with
the effects of Y27632 and C646 on LPA-induced ac-NF-kB levels,
while each inhibitor alone showed no signiﬁcant effect
(Fig. 3CeF).
The most important issue in this study is the downstream of
Rho/ROCK signaling activated through LPA1 leads to gene silencing
of myelin-related molecules. This is because most of studies
regarding Rho/ROCK signaling are related to morphological func-
tions, and gene regulation of myelin-related molecules is often
reported in terms of transactivation systems (12,13). Furthermore,
the role of ac-NF-kB in the gene repression is also unique, since
NFkB itself is known to activate the transcription of inﬂammation-
related genes (14). In our preliminary study using another type of
Schwann cell line, IMS32 (15), we failed to detect the LPA-mediated
gene repression of myelin-related molecules. So the use of S16 cells
could be beneﬁcial for the study of LPA1-mediated cellular signaling
of down-regulation of myelin-related gene, and for future drug
discovery strategy to suppress demyelination-related neuropathic
pain.
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Fig. 3. LPA elicits acetylation of NFkB through LPA1-Rho/ROCK-p300 pathway. Western blotting analysis after exposure of 1 and 10 mM LPA for 3 h after pretreatment with either
0.1% BSA (vehicle), 1 mM Ki16425 (A and B), 1 mM Y27632 (C and D) or 1 mM C646 (E and F) for 30 min in S16 cells. b-actin was used as a loading control. A representative blot is
shown. The intensity of the bands was analyzed using ImageJ software. Statistical analyses were performed using one-way ANOVA (mean ± SEM, n ¼ 3). *p < 0.05 and **p < 0.01
versus vehicle control. #p < 0.05 and ##p < 0.01 versus 1 mM LPA. yp < 0.05 and yyp < 0.01 versus 10 mM LPA. N.S. represents no signiﬁcant.
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